Myositis patients, register to join us for real-time video support, the third Saturday of each month at 3 PM...
Myositis patients, register to join us for real-time video support, the first Wednesday of each month at 7 PM...
Myositis patients, join us for real-time video support, the third Saturday of each month at 3 PM Eastern.
Myositis patients, join us for video support, discuss Covid-19 and its impact on our #MyositisLIFE, the first Wednesday of...
Myositis patients, join us for video support on April 18, 2020, at 3 PM Eastern Time for discussions about...
Real-time video support for myositis patients on April 1st at 7 PM ET. For polymyositis, dermatomyositis, immune-mediated necrotizing myopathy,...
Introduction to the PRESIDIO Clinical Trial of KZR-616 for the Treatment of Polymyositis and Dermatomyositis
, , Featured, Video
Dr. Mary Katherine (MK) Farmer, MD, Rheumatologist and Senior Medical Director at Kezar Life Sciences, joined us live online...
Experience of pain and fatigue in adult idiopathic inflammatory myopathies (IIM)
, , Featured, News, Video
Watch the video, "Experience of pain and fatigue in adult idiopathic inflammatory myopathies (IIM)" with Helene Alexanderson, Ph.D. with...
Myositis Support and Understanding (MSU) partners with the University of Pittsburgh for a new NIH-sponsored study entitled, “Myositis Patient...
Skin findings seen with myositis autoantibodies and treatment of skin in dermatomyositis
, , Dermatomyositis, Featured, News, Video
Dr. Victoria Werth joined us live online for a video education session titled, "Skin findings seen with myositis autoantibodies...
A session that covered safety and effects of exercise in recent onset and established adult and juvenile IIM. Dr....
DETERMINE - a Phase 3 trial designed to evaluate the efficacy and safety of lenabasum for the treatment of adults...
Corbus launches DETERMINE, a Phase 3 trial of lenabasum for the treatment of dermatomyositis
, , Dermatomyositis, Featured, News
New locations announced July 9, 2019. DETERMINE is a double-blind, placebo-controlled 1-year study designed to test the efficacy and...
Myositis and Cancer: Risk highest for carriers of anti-TIF1 antibody
, , Dermatomyositis, Featured, News
The research found that DM patients with the anti-transcriptional intermediary factor 1 (anti-TIF1) antibody were more than three times...
During Myositis Awareness Month, May 2018, we placed a large focus on patient education by hosting some of the...
EULAR/ACR Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
, , Featured, News
Clinical trials and studies require patient groups in clearly defined categories, but the multiple diagnostic and classification criteria used...
Dermatomyositis Patients with a Certain Type of Autoantibodies at Higher Risk of Skin Eruptions with Use of Hydroxychloroquine
, , Featured, News
In this study, the researchers set out to determine if there was a distinction between the type of autoantibodies...
Today, Corbus Pharmaceuticals announced that the European Commission has approved orphan designation for lenabasum in the treatment of dermatomyositis...
Corbus Pharmaceuticals announced today that they will proceed with a Phase 3 clinical trial to evaluate the efficacy and...
"New Developments on the Role of Itch in Dermatomyositis", based on new research published in the British Journal of...
Get Support!
